Yutrepia (Treprostinil) for Pulmonary Hypertension

Overview
Yutrepia is approved by the U.S. Food and Drug Administration (FDA) for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. It is prescribed to improve exercise ability in adults with these conditions. Yutrepia is also known by its drug name, treprostinil.

Yutrepia is a prostacyclin mimetic, a type of drug that mimics the action of prostacyclin — a natural substance that helps widen blood vessels and prevent blood clotting. In people with pulmonary hypertension, this helps reduce the pressure in the lungs' arteries and improves the heart’s ability to pump blood, leading to better exercise tolerance.

How do I take it?
Prescribing information states that Yutrepia is administered as an inhalation powder using a special inhaler device. It must not be swallowed. It should be taken three to five times per day, with each capsule’s contents inhaled in two breaths. The drug should be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Yutrepia include cough, headache, throat irritation, and dizziness.

Rare but serious side effects may include symptomatic hypotension (low blood pressure that causes noticeable symptoms), increased risk of bleeding due to inhibition of platelet aggregation, and bronchospasm (tightening of airway muscles), especially in individuals with a history of airway hyperreactivity. 

For more information about this treatment, visit:

Yutrepiatm (Treprostinil) Inhalation Powder, for Oral Inhalation Use — Liquidia